Metagenomi Therapeutics (MGX) Return on Invested Capital (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Return on Invested Capital data on file, last reported at 0.01% in Q1 2026.

• Return on Invested Capital for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, up 1.0% from the prior year.
• Return on Invested Capital declined to 0.01% in Q1 2026 per MGX's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.01% in Q4 2023 and troughed at 0.01% in Q1 2024.
• A 4-year average of 0.0% and a median of 0.0% in 2025 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Return on Invested Capital declined 2 bps in 2024, then rose 1 bps in 2025.
• A 4-year view of Return on Invested Capital shows it stood at 0.01% in 2023, then tumbled by 128 bps to 0.0% in 2024, then sank by 68 bps to 0.01% in 2025, then fell by 10 bps to 0.01% in 2026.
• Business Quant data shows MGX's Return on Invested Capital at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.